Skip to main content

What Boston Scientific's Quarter ended Sep 30, 2026 10-Q says: 9 signals

Boston Scientific filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and cost reduction.

Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn

Get Boston Scientific's live signals in Claude or ChatGPT, or by API

AskWhat changed at Boston Scientific this week? Use Autobound signals for bostonscientific.com.
Filed
Nov 2, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
17

Source: Autobound Signal API · 113 signals tracked for Boston Scientific · updated

10-Q · latest 10

What Boston Scientific's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 9 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR

Showing 10 of 17 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Boston Scientific earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Restructuring program targets over $500M in savings across three yearsManagement initiated a comprehensive restructuring program targeting more than $500 million in cumulative savings over the next three years, with over half expected to be achieved exiting 2027. The program targets organizational delayering, back-office shared services transformation, travel and external vendor reductions, and supply chain optimization leveraging AI. This represents an active...
Electrophysiology market share erodes amid intense competitive PFA dynamicsElectrophysiology sales declined 5% year-over-year in Q3 (down 8% in the U.S.), as market share in pulsed field ablation eroded following new rival technology entries and differing form factors. Share loss was accelerated by the recent cyber incident, and management expects continued share erosion through 2027 until the FARAWAVE Ultra launch in early 2028. This presents opportunities for...
Cybersecurity incident caused two-week operational disruption and sales lossA global cyber incident caused an 8-business-day disruption, shutting down manufacturing and shipping and reducing Q3 organic revenue growth by approximately 300 basis points ($0.07 adjusted EPS). Operations resumed on September 8, but management expects an additional 200 to 300 basis points headwind in Q4 as customer inventory normalizes. This operational vulnerability creates sales...
Co-funding agreement signed with Blackstone Life Sciences for VitalistBoston Scientific signed an agreement with Blackstone Life Sciences to co-fund clinical and development efforts for its Vitalist Circulatory Support System targeting acute myocardial infarction cardiogenic shock. Blackstone funding will offset R&D expenses as incurred, in exchange for repayment of funded amounts plus commercial royalties starting around 2030. The partnership allows the company...
Joe Fitzgerald appointed Chief Operating Officer to oversee sectorsJoe Fitzgerald has been elevated to Chief Operating Officer as part of a structural reorganization breaking up business sectors to increase accountability and launch execution speed. Structural changes at this level frequently trigger reviews of operational reporting systems, commercial software, and vendor relationships across business units. The change comes as the company navigates product...
Expanding volume-based procurement pricing pressures impact sales in ChinaPricing dynamics in China have become more challenging due to expanding Volume-Based Procurement (VBP) impacting Urology and Endoscopy businesses, causing Asia-Pacific sales to decline 1% operationally. Management expects these pricing headwinds to escalate into 2027 and moderate China growth to single digits until lapping VBP in Q4 2027. This pressure indicates a critical need for regional...

Signal API · MCP

Track Boston Scientific with the Signal API

One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bostonscientific.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Boston Scientific 10-Q

When did Boston Scientific file its latest 10-Q?
Boston Scientific filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 2, 2026. The one before it was filed on Aug 3, 2026.
What did Boston Scientific disclose in its latest 10-Q?
From the filing dated Nov 2, 2026: Board approved 2026 Restructuring Plan with expected charges of $700M to $800M
What did Boston Scientific say on its recent earnings calls?
Q3 FY2026: Restructuring program targets over $500M in savings across three years (dated Oct 28, 2026).
Where can I read Boston Scientific's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/bsx-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →